Tag Archives: Relapsed/Refractory multiple myeloma

US FDA Approves Tecvayli® (Teclistamab-cqyv) for Relapsed/Refractory Multiple Myeloma (RRMM)

On October 25, 2022, the US FDA granted accelerated approval to Tecvayli® (teclistamab-cqyv, Janssen Biotech, Inc.) for adult patients with […]

October 28, 2022

The US FDA approves Sarclisa together with Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

The FDA has approved Sarclisa, together with Kyprolis and dexamethasone (Kd), in order to treat adult patients with the relapsed […]

April 5, 2021

Triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib for RRMM

According to phase-I/IIa findings from the ANCHOR (OP-104) trial that were introduced during the second EMN (European Myeloma Network) Meeting, […]

March 18, 2021

Teclistamab Demonstrates Continued Promise in Relapsed/Refractory MM

According to outcomes from an ongoing phase 1 study, a bispecific BCMA (B-cell maturation antigen) x CD3 antibody named Teclistamab […]

March 16, 2021